Compare Adaptive Biotechnologies Corp (ADPT) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs TransMedics Group Inc — how do they compare? Adaptive Biotechnologies Corp trades at $24.02 (market cap $3.84B), while TransMedics Group Inc trades at $70.78 (market cap $2.45B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Adaptive Biotechnologies Corp for 37 Days and TransMedics Group Inc for 25 Days on average.
| ADPT | TMDX | |
|---|---|---|
Market Cap | $3.84B | $2.45B |
Volume | 1,940,957 | 1,067,831 |
Sector | Health | Health |
52-Week High | $29.84 | $150.42 |
52-Week Low | $12.41 | $61.99 |
Typical Hold Time | 37 Days | 25 Days |
Enterprise Value | $3.90B | $2.85B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.58, down 0.16% on the day, with a bearish technical signal despite recent 52-week highs near $28.78. The company shows improving fundamentals with revenue growth to $277M in 2025 and narrowing losses, though still reporting negative net income margins. Recent news highlights MRD testing advancements and NCCN guideline updates, while analyst consensus remains bullish with a $31.58 price target.
The outlook suggests potential upside from current levels if execution continues improving, but risks include sustained profitability challenges and competitive pressures in biotechnology. Investors should weigh strong analyst support against the company's ongoing transition to profitability and market volatility concerns.
TransMedics Group (TMDX) trades at $76.52, showing mixed technical signals with a bearish moving average trend but neutral oscillators. The company maintains strong profitability with 22.69% net income margin and 36.28% ROE, though recent quarterly earnings have missed expectations. Analyst sentiment remains positive with 69% buy ratings and a $99.63 consensus target, representing 30% upside potential. Recent news highlights insider buying activity but also ongoing fiduciary duty investigations.
The stock presents a compelling value opportunity given the significant discount to analyst targets, supported by strong fundamentals and growth prospects. However, investors face risks from the bearish technical setup, margin pressure from increased investment spending, and legal uncertainties surrounding fiduciary investigations that could impact near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
